title: [Hematopoietic Reconstitution and Prognosis of HLA Matched and Haploidentical Hematopoietic Stem Cell Transplantation Using Modified FC/ATG Conditioning for Treatment of Severe Aplastic Anemia].
abstract: OBJECTIVE
  To analyse the feasibility and compare differences between hematopoietic reconstitution and prognosis of patients with severe aplastic anemia(SAA) after matched sibling donor (MSD) or haploidentical family donor (HFD) hematopoietic stem cell transplantation (HSCT) using the modified FC/ATG conditioning.
  
  
  METHODS
  The clinical data of 56 patients with SAA who received HSCT in First Affiliated Hospital of Chinese PLA General Hospital from January 2011 to June 2016 were analyzed retrospectively. The hematopoietic reconstitution, graft verus host disease (GVHD), transplantation related toxicity (TRT) and prognosis after transplantation were compared. Furthermore, the modifed conditioning FC/ATG included low-dose cyclophosphamide (total dose 100 mg/kg), infustion of third-party donor-derived mesenchymal stem cells.
  
  
  RESULTS
  All 56 patients with MSD-HSCT or HFD-HSCT achieved hematopoietic reconstitution. Among them, not only the recovery of neutrophils and platelets, but also the incidences of III-IV aGVHD, extensive cGVHD and TRT were not significantly different (the P value were 0.58, 0.61, 0.73, 0.73 and 0.67, respectively). After following-up for 32(2-66) months, 48 patients alive well, the 1-year overall survival rates were 86% in HFD-HSCT group and 89% in MSD-HSCT group, respectively (P=0.58).
  
  
  CONCLUSIONS
  After HSCT using the modifed FC/ATG conditioning, patients with SAA achieved stable engraftment, low toxicity, mild GVHD and excellent outcomes. Furthermore, the HFD-HSCT achieved comparable outcomes to MSD-HSCT and may be served as an alternate therapy for patients with SAA.
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
authors.forename: Li
authors.initials: L
authors.lastname: Wang
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
authors.forename: Ya-Mei
authors.initials: YM
authors.lastname: Wu
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
authors.forename: Yong-Bin
authors.initials: YB
authors.lastname: Cao
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
authors.forename: Xiao-Hong
authors.initials: XH
authors.lastname: Li
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
authors.forename: Li-Xin
authors.initials: LX
authors.lastname: Xu
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
authors.forename: Hai-Tao
authors.initials: HT
authors.lastname: Wang
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
authors.forename: Ya-Hui
authors.initials: YH
authors.lastname: Gao
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China. E-mail: xiongwuxiao@sohu.com.
authors.forename: Xiao-Xiong
authors.initials: XX
authors.lastname: Wu
mesh_terms: D000741:Anemia, Aplastic; D001792:Blood Platelets; D003520:Cyclophosphamide; D006086:Graft vs Host Disease; D006680:HLA Antigens; D006239:Haplotypes; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015994:Incidence; D059630:Mesenchymal Stem Cells; D009504:Neutrophils; D011379:Prognosis; D012189:Retrospective Studies; D035781:Siblings; D014019:Tissue Donors; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous
chemical_list: D006680:HLA Antigens; D003520:Cyclophosphamide